INMD Key Statistics, Chart & Performance
The current stock price of INMD is 15.56 USD. In the past month the price increased by 7.84%. In the past year, price decreased by -2.2%.
INMD Latest News, Press Relases and Analysis
INMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.43 | 220.65B | ||
| ISRG | INTUITIVE SURGICAL INC | 69.94 | 213.46B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.6 | 146.92B | ||
| SYK | STRYKER CORP | 27.8 | 140.03B | ||
| BDX | BECTON DICKINSON AND CO | 14.18 | 58.35B | ||
| IDXX | IDEXX LABORATORIES INC | 57.04 | 57.44B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.15 | 49.44B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.87 | 39.46B | ||
| RMD | RESMED INC | 25.17 | 36.37B | ||
| DXCM | DEXCOM INC | 37.73 | 27.37B | ||
| PODD | INSULET CORP | 64.66 | 20.79B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.39 | 18.26B |
Related stock screener links
About INMD
Company Profile
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Company Info
INMODE LTD
Tavor Building, Sha'ar Yokneam, Pob 533
Yokneam 2069200 IL
CEO: Moshe Mizrahy
Employees: 599
Phone: 97249097470
INMODE LTD / INMD FAQ
Can you describe the business of INMODE LTD?
InMode Ltd. designs, develops, manufactures and markets minimally-invasive aesthetic medical products. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The firm have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Can you provide the latest stock price for INMODE LTD?
The current stock price of INMD is 15.56 USD. The price increased by 0.06% in the last trading session.
Does INMODE LTD pay dividends?
INMD does not pay a dividend.
How is the ChartMill rating for INMODE LTD?
INMD has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What do analysts say about INMODE LTD (INMD) stock?
14 analysts have analysed INMD and the average price target is 16.93 USD. This implies a price increase of 8.82% is expected in the next year compared to the current price of 15.56.
Can you provide the growth outlook for INMODE LTD?
The Revenue of INMODE LTD (INMD) is expected to decline by -8.35% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for INMODE LTD?
INMODE LTD (INMD) currently has 599 employees.
INMD Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to INMD. When comparing the yearly performance of all stocks, INMD is a bad performer in the overall market: 66.03% of all stocks are doing better.
INMD Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to INMD. INMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
INMD Financial Highlights
Over the last trailing twelve months INMD reported a non-GAAP Earnings per Share(EPS) of 1.58. The EPS decreased by -23.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.1% | ||
| ROA | 20.39% | ||
| ROE | 22.93% | ||
| Debt/Equity | 0 |
INMD Forecast & Estimates
14 analysts have analysed INMD and the average price target is 16.93 USD. This implies a price increase of 8.82% is expected in the next year compared to the current price of 15.56.
For the next year, analysts expect an EPS growth of -9.69% and a revenue growth -8.35% for INMD